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A B S T R A C T
Background
Cardiogenic shock (CS) is a state of critical end-organ hypoperfusion due to a primary cardiac disorder. For people with refractory CS
despite maximal vasopressors, inotropic support and intra-aortic balloon pump, mortality approaches 100%. Mechanical assist devices
provide mechanical circulatory support (MCS) which has the ability to maintain vital organ perfusion, to unload the failing ventricle thus
reduce intracardiac filling pressures which reduces pulmonary congestion, myocardial wall stress and myocardial oxygen consumption.
This has been hypothesised to allow time for myocardial recovery (bridge to recovery) or allow time to come to a decision as to whether
the person is a candidate for a longer-term ventricular assist device (VAD) either as a bridge to heart transplantation or as a destination
therapy with a long-term VAD.
Objectives
To assess whether mechanical assist devices improve survival in people with acute cardiogenic shock.
Search methods
We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid) and Web of Science Core Collection in November 2019. In addition, we searched
three trials registers in August 2019. We scanned reference lists and contacted experts in the field to obtain further information. There were
no language restrictions.
Selection criteria
Randomised controlled trials on people with acute CS comparing mechanical assist devices with best current intensive care management,
including intra-aortic balloon pump and inotropic support.
Data collection and analysis
We performed data collection and analysis according to the published protocol.
Primary outcomes were survival to discharge, 30 days, 1 year and secondary outcomes included, quality of life, major adverse
cardiovascular events (30 days/end of follow-up), dialysis-dependent (30 days/end of follow-up), length of hospital stay and length of
intensive care unit stay and major adverse events.
We used the five GRADE considerations (study limitations, consistency of e"ect, imprecision, indirectness, and publication bias) to assess
the quality of a body of evidence as it relates to the studies which contribute data to the meta-analyses for the prespecified outcomes
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Summary statistics for the primary endpoints were risk ratios (RR), hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals
(CIs).
Main results
The search identified five studies from 4534  original citations reviewed. Two studies included acute CS of all causes randomised
to treatment using TandemHeart percutaneous VAD and three studies included people with  CS secondary to acute myocardial
infarction who were randomised to Impella CP or best medical management. Meta-analysis was performed only to assess the 30-day
survival as there were insu"icient data to perform any further meta-analyses. The results from the five studies with 162 participants showed
mechanical assist devices may have little or no e"ect on 30-day survival (RR of 1.01 95% CI 0.76 to 1.35) but the evidence is very uncertain.
Complications such as sepsis, thromboembolic phenomena, bleeding and major adverse cardiovascular events were not infrequent in
both the MAD and control group across the studies, but these could not be pooled due to inconsistencies in adverse event definitions and
reporting.
We identified four randomised control trials assessing mechanical assist devices in acute CS that are currently ongoing.
Authors' conclusions
There is no evidence from this review of a benefit from MCS in improving survival for people with acute CS. Further use of the technology,
risk stratification and optimising the use protocols have been highlighted as potential reasons for lack of benefit and are being addressed
in the current ongoing clinical trials.
P L A I N   L A N G U A G E   S U M M A R Y
Mechanical heart pumps to aid a heart that fails suddenly
Background
Conditions that prevent the heart pumping e"ectively remain the leading cause of death globally. A heart attack is the most common
condition that causes the heart pump to fail (called cardiogenic shock), but other causes exist such as viral infections, heart valve disease
and problems with the muscle. When the heart muscle has been damaged so extensively that it can no longer pump e"ectively function has
to be improved or organ damage and death will occur. Even with the best treatments that we currently have, the risk of dying is extremely
high. Mechanical assist devices that can help the heart to pump more e"ectively have been developed so that the heart can recover from
the insult.
However, the evidence for these treatments is scare and the aim of this review is to assess if these devices do help more people to survive.
We assessed randomised control trials (clinical studies where people are randomly put into one of two or more treatment groups) where
these devices were used and compare the outcome of these people to those who did not receive a device and received best medical
treatment (with medicines to help the heart to pump).
Results
The evidence is current to 25 November 2019.
We identified five trials that enrolled 162 people in shock due to their heart failing. These people were randomised to using mechanical
assist devices with current best management practice or current best medical management alone (which includes medicines to help the
heart to pump more e"ectively).
The quality of the evidence was very low, due to di"iculties in accounting for biases (one cannot hide the fact that a person receives a
mechanical assist device, di"iculty in enrolling participants, gaining consent when a person is very close to dying, and variations in the
protocols on the timing of the devices and the types of devices used).
From the data, there was little or no e"ect on survival at 30 days if a device was used alongside current best medical management or
current best medical management alone. However, we are uncertain about these findings.
Complications such as sepsis, thromboembolic phenomena, bleeding and major adverse cardiovascular events were not infrequent in
both the MAD and control group across the studies, but these could not be pooled due to inconsistencies in adverse event definitions and
reporting.
Currently there are four ongoing trials. They are assessing if they can improve outcomes by selecting the people who would most likely
have a benefit.
Conclusions
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In conclusion, this review was unable to assess if mechanical assist devices help people with cardiogenic shock due to their heart failing.
We await the results of the ongoing trials, which we anticipate will help clarify whether these devices will help people to survive with a
full recovery or not.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Mechanical assist devices compared to intra-aortic balloon pump for acute cardiogenic shock at 30-day follow-up
MAD compared to IABP for acute cardiogenic shock 30-day follow-up
Patient or population: people with acute cardiogenic shock





























































3 studies described MACE events in a very heterogeneous manner without any clear definitions
in any of the studies (Ouweneel 2017; Seyfarth 2008; Thiele 2005). CVA occurred in 1 participant
who had a MAD and 1 participant who had IABP only (both in Ouweneel 2017 and both CVA were
ischaemic). Ouweneel 2017 was the only study to describe if any cases had myocardial reinfarction
reporting that this occurred in 1 participant who had MAD and 2 participants who had IABP only.
Ouweneel 2017 described that 1 participant had a major vascular complication, with a retroperi-
toneal bleed after percutaneous MAD insertion. Thiele 2005 described that 7 participants devel-
oped limb ischaemia following insertion of a 17-French arterial cannula. Limb ischaemia could be

































































































































Seyfarth 2008 described limb ischaemia requiring surgery after device explantation in 1 partici-













Ouweneel 2017 reported 8/24 (33%) participants in MAD group and 7/24 (29%) in IABP group re-
quired dialysis with duration of treatment (median) 17 (25th to 75th percentile 5–29) days in MAD










1 study described length of stay Ouweneel 2017 MAD median 16 days (25th to 75th percentile 2–









1 study described length of ICU stay Ouweneel 2017 MAD median 7 days (25th to 75th percentile 3–














Adverse events were heterogeneous. Burkhoff 2006 had 1 device failure TandemHeart blood clot
in the cannula, also described 21.5% of participants in MAD group developed sepsis vs 35.7% in
IABP group. Ouweneel 2017 stated that 33% in MAD group had significant bleeding vs 8% in IABP.
Thiele 2005 stated that 61% in MAD group had evidence of DIC vs 15% in IABP group.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; CVA: cardiovascular accident; DIC: disseminated intravascular coagulation; IABP: intra-aortic balloon pump; ICU: intensive care unit; MACE: major
adverse cardiovascular events; MAD: mechanical assist device; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level for study limitations: the majority of studies were at high or unclear risk of bias for at least one key domain.




































































Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
See Appendix 1 for a glossary of terms.
Acute cardiogenic shock (ACS) is a state of inadequate organ
perfusion secondary to acute heart failure (Shekar 2016). This is
characterised by persistent hypotension (systolic blood pressure
less than 80 mmHg to 90 mmHg or mean arterial blood pressure
30 mmHg lower than baseline, for more than 30 minutes) with
reduction in Cardiac Index to less than 1.8 L/minute/m2 without
haemodynamic support or less than 2.0 L/minute/m2 to 2.2
L/minute/m2 with support and elevated filling pressures (leM
ventricular end-diastolic pressure (LVEDP) greater than 18 mmHg
or right ventricular end-diastolic pressure (RVEDP) greater than
10 mmHg to 15 mmHg), a pulmonary capillary wedge pressure
greater than 15 mmHg in the setting of adequate or elevated filling
pressure, and clinical features of hypoperfusion (cool extremities,
decreased urine output, or altered sensorium) (Mandawat 2017;
Reynolds 2008; Rihal 2015).
Despite advances in the management of cardiogenic shock,
it remains the leading cause of death in hospitalised people,
regardless of aetiologies (Chung 2012; WHO 2018). The incidence
of ACS has increased two-fold from approximately 55,123 in 2004
to 126,555 in 2014, according to the largest publicly available data
in the USA (Mandawat 2017). Furthermore, the prognosis of ACS
remains poor, with only 48% of people surviving from diagnosis
to hospital discharge, despite higher rates of revascularisation and
use of intra-aortic balloon pumps (IABP) (Mandawat 2017).
Myocardial infarction with leM ventricular failure is the most
common cause of cardiogenic shock, and cardiogenic shock
occurs in approximately 5% to 8% of people hospitalised with ST
elevation myocardial infarction (STEMI) and 2.5% of non-STEMI
cases (Babaev 2005; Fox 2007; Hasdai 2000). When cardiogenic
shock complicates an acute myocardial infarction, the reported
mortality rate is between 85% and 90% (Goldberg 2001). Any cause
of acute and severe leM ventricular or right ventricular dysfunction
can lead to cardiogenic shock. Acute myopericarditis, Takotsubo
cardiomyopathy, and peripartum cardiomyopathy can all lead
to reversible ventricular dysfunction which have good long-term
prognosis, but only if the person can be supported through the
acute phase of cardiac failure and cardiogenic shock (Emmert 2011;
Howell 2016; Kato 1999; Omerovic 2016; Zalewska-Adamiec 2016).
Description of the intervention
For people with refractory cardiogenic shock despite maximal
vasopressors, inotropic support and IABP, mortality approaches
100% with few people surviving (Hochman 2001). Survival in these
cases may be possible by providing complete circulatory support
with a mechanical assist device (MAD) (Hendry 1999; Hill 1986;
Holman 1995).
MADs provide mechanical circulatory support (MCS) that has
the ability to maintain vital organ perfusion, to unload the
failing ventricle thus reducing intracardiac filling pressures which
reduces pulmonary congestion, myocardial wall stress and
myocardial oxygen consumption. MADs also have the ability
to augment coronary perfusion by supporting the circulation
during procedures which aim to treat the underlying cause
of cardiogenic shock, such as revascularisation or ablation of
ventricular arrhythmia (Friedel 1992; Rihal 2015). This can allow
time for myocardial recovery (bridge to recovery) or allow time to
come to a decision as to whether the person is a candidate for
a longer-term ventricular assist device (VAD) either as a bridge to
heart transplantation or as a destination therapy with a long-term
VAD (Copeland 2004).
How the intervention might work
Current devices can be divided into categories: short-term versus
long-term devices; paracorporeal versus intracorporeal; pulsatile
versus continuous flow devices; full versus partial support devices;
percutaneous versus surgical; and assist devices versus complete
heart replacement (total artificial heart) (Sellke 2010).
In people presenting with critical circulatory instability, the
chosen mechanical assistance should be rapidly available and
easily implantable. Standard cardiopulmonary bypass is designed
to ensure minutes to hours of support for people undergoing
cardiac surgery. Extracorporeal membrane oxygenation (ECMO)
provides continuous flow support to people with respiratory,
cardiac or combined cardiopulmonary failure for days to weeks.
Deoxygenated blood is drained from the venous system, the
pulmonary system is bypassed by placing an oxygenator in parallel
with the native lungs and pumped in a continuous manner using a
centrifugal or roller pump back to the arterial circulation (Bartlett
2010). Cannulation can be obtained centrally (blood being drained
directly from the right atrium and returned to the proximal
ascending aorta) or peripherally (blood draining from the proximal
femoral or jugular vein and returned to the carotid axillary or
femoral artery), typically using the Seldinger technique, via an open
or percutaneous approach (Chamogeorgakis 2013).
Venoarterial ECMO is available for cardiac or cardiopulmonary
failure as a bridge to recovery, a bridge to definitive VAD or bridge
to heart transplantation (Squiers 2016).
Similarly, short-term VADs can be rapidly implantable and provide
extracorporeal or paracorporeal pulsatile or continuous flow.
VADs support the function of the leM ventricle (leM ventricular
assist device (LVAD)), right ventricle (right ventricular assist device
(RVAD)) or both ventricles (biventricular assist device (BiVAD))
depending on what is required for that particular patient. They do
not include an oxygenator, thus providing isolated cardiac support.
These devices are more expensive but allow the people longer
duration of circulatory support and greater opportunity to mobilise
(Rihal 2015).
Why it is important to do this review
The leading cause of death internationally is cardiovascular
disease, and cardiogenic shock is the penultimate point in which
there is an opportunity to intervene (Lü 2016).
Cardiac surgeons are faced with increasingly complex cases with
significant comorbidities, and with quality indexes, such as failure
to rescue those who develop complications (e.g. postcardiotomy
cardiogenic shock) being increasingly assessed. In order to operate
on such complex cases, having the knowledge of the best current
evidence will provide hospital trusts with the essential information
in providing the necessary equipment and in training sta" in the use
of mechanical support devices.
Mechanical assist devices for acute cardiogenic shock (Review)
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The National Institute for Health and Care Excellence (NICE)
guidelines: Acute heart failure: diagnosis and management, state
that "at an early stage, the specialist should have a discussion with
a centre providing MCS about people with potentially reversible
severe acute heart failure or people who are potential candidates
for heart transplantation" (NICE 2014).
The 2016 European Society of Cardiology guidelines for the
diagnosis and treatment of acute and chronic heart failure include
MCS as a treatment option for people who cannot be stabilised on
medical treatment alone. In addition to the uses described above,
MCS, particularly ECMO, can be used as a 'bridge to decision' in
people with cardiogenic shock to achieve haemodynamic stability,
to allow consideration of long-term MCS and heart transplant to be
evaluated (Ponikowski 2016).
The American Heart Association (AHA) and International Society
for Heart and Lung Transplantations guidelines recommend
patients with persistent cardiogenic shock with or without end-
organ hypoperfusion, should be evaluated for MCS candidacy
by a multidisciplinary team with expertise in the selection,
implantation, and management of MADs (AHA 2012; ISHLT 2013).
The most recent AHA scientific statement on the contemporary
management of cardiogenic shock state, "We suggest that
temporary MCS devices can be inserted in patients who are not
expected to recover as early as possible in the course of CS
[cardiogenic shock] as a bridge to recovery, bridge to a bridge, BTT,
or bridge to decision strategy in appropriately selected patients
with CS" (AHA 2017).
Many cardiology/cardiothoracic centres do not have timely access
to temporary mechanical support devices. This review aims to
assess the e"ectiveness of this treatment which would be valuable
in guiding patient management and service planning.
O B J E C T I V E S
To assess whether mechanical assist devices improve survival in
people with acute cardiogenic shock.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) comparing MADs
with best current intensive care management, including IABP and
inotropic support. We included studies reported as full-text, those
published as abstract only and unpublished data. We did not
include cross-over trials as we were looking at survival data in the
setting of people with an exceedingly high mortality risk.
Types of participants
We included all participants, irrespective of age (adults and
children), with a diagnosis of ACS secondary to any cause. ACS
was defined as "a state of organ hypoperfusion secondary to acute
cardiac failure" (Shekar 2016). This is characterised by persistent
hypotension (systolic blood pressure less than 80 mmHg to 90
mmHg or mean arterial blood pressure 30 mmHg lower than
baseline, for more than 30 minutes) with reduction in Cardiac Index
to less than 1.8 L/minute/m2 without haemodynamic support or
less than 2.2 L/minute/m2 with support, and a pulmonary capillary
wedge pressure greater than 15 mmHg in the setting of adequate or
elevated filling pressure (Reynolds 2008; Rihal 2015).
We included studies with a subset of eligible participants in the
review. When more than one of the included trials was found to
have less than 75% of people with the diagnosis of interest, we
accepted that this reduces the validity of the results.
Types of interventions
The intervention group was any participant treated with a
MAD, including ECMO, LVAD, RVAD or BiVAD, compared to the
control group which was treated with best current intensive care
management, including inotropic support and IABP.
Types of outcome measures
The reporting of outcomes was not a criteria for inclusion in the
review.
Primary outcomes
1. Survival (measured to: discharge; 30 days; 1 year; end of follow-
up).
2. Survival (measured to: transplant; unsupported cardiac
function; end of follow-up).
Secondary outcomes
1. Quality of life (using a validated quality of life scale or
questionnaire, measured to: discharge; 30 days; 6 months; 1
year; end of follow-up).
2. Major adverse cardiovascular events (measured to: discharge;
30 days; 6 months; 1 year; end of follow-up):
a. cerebrovascular accidents (persistent central neurological
deficit for greater than 72 hours);
b. myocardial infarction;
c. acute limb ischaemia.
3. Dialysis-dependent (measured to: discharge; 30 days; 1 year;
end of follow-up).
4. Length of hospital stay and length of intensive care unit stay.
5. Major adverse events, for example, deep sternal wound
infection, prolonged ventilation greater than 72 hours
(measured to: discharge; 30 days; 6 months; 1 year; end of
follow-up).
Search methods for identification of studies
Electronic searches
We identified trials through systematic searches of the following
bibliographic databases on 25 November 2019:
1. CENTRAL, Issue 11 (the Cochrane Library);
2. Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
MEDLINE Daily and MEDLINE (Ovid, 1946 to 22 November 2019);
3. Embase (Ovid, 1980 to 2019 week 47);
4. Web of Science Core Collection (Clarivate Analytics, 1900 to 25
November 2019).
We adapted the preliminary search strategy for MEDLINE (Ovid)
for use in the other databases (Appendix 2). We applied the
Cochrane sensitivity-maximising RCT filter to MEDLINE (Ovid) and
Mechanical assist devices for acute cardiogenic shock (Review)









Cochrane Database of Systematic Reviews
adaptations of it to the other databases, except CENTRAL (Lefebvre
2011).
We also conducted a search of ClinicalTrials.gov
(www.ClinicalTrials.gov), the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP) Search Portal
(apps.who.int/trialsearch/), the UK Clinical Research Network
Portfolio Database (public.ukcrn.org.uk), and Centerwatch
(www.centerwatch.com) on 4 August 2019.
We searched all databases from their inception and we imposed no
restriction on language of publication.
We searched relevant manufacturers' websites for trial information
on 4 August 2019. Manufacturers of MADs that we have
identified in previous searches were: Abbott (www.thoratec.com;
www.sjmglobal.com), Getinge AB (www.maquet.com), Medtronic
(www.medtronic.com), LivaNova (www.livanova.com), Hemovent
(www.hemoventgmbh.com), ABIOMED (www.abiomed.com),
www.reliantheart.com, Novacor (www.novacor.co.uk), MyLVAD
(www.mylvad.com), Jarvik Heart (www.jarvikheart.com,
www.terumoheart.net, www.sunshineheart.com).
Searching other resources
We checked reference lists of included studies and review articles
for additional references. We contacted trial authors for missing
data and through peer groups, identified any other ongoing trials.
We examined any relevant retraction statements and errata for
included studies.
Data collection and analysis
Selection of studies
Two teams of two review authors (JS, TN and CC, PA)
independently screened titles and abstracts of all potential studies
we identified as a result of the search for inclusion and code
them as 'retrieve' (eligible or potentially eligible/unclear) or 'do
not retrieve'. If there were any disagreements, a fiMh review
author arbitrated (KB). We retrieved the full-text study reports/
publications and two review authors (TN, JS) independently
screened the full-text and identified studies for inclusion, and
identified and recorded reasons for exclusion of the ineligible
studies. We resolved any disagreements through discussion or, if
required, we consulted a third review author (KB). We identified
and excluded duplicates and collated multiple reports of the same
study so that each study, rather than each report, was the unit
of interest in the review. We recorded the selection process in
su"icient detail to complete a PRISMA flow diagram (Liberati 2009).
Data extraction and management
We use Covidence (www.covidence.org), and extracted study
characteristics and outcome data onto a form piloted on at least
one study in the review. We included studies irrespective of whether
measured outcome data were reported in a usable way.
Two review authors (CC and JS) extracted the following study
characteristics.
1. Methods: study design, total duration of study, number of study
centres and location, study setting, withdrawals, date of study.
2. Participants: number of participants randomised to the
intervention, number of participants lost to follow-up, number
of participants analysed, mean age, age range, gender, cause
of cardiogenic shock, diagnostic criteria, baseline lung function,
smoking history, lactate prior to initiating MCS.
3. Interventions: type of MADs, duration from diagnosis to
intervention, duration of treatment, comparison, concomitant
medications.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported, number lost to follow-up,
reasons for loss to follow-up.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (CC and JS) independently extracted outcome
data from included studies. We resolved disagreements by
consensus or by involving a third review author (PA). One review
author (TN) transferred data into Review Manager 5 (Review
Manager 2014). We double-checked that data were entered
correctly by comparing the data presented in the review with the
study reports. A second review author (JS) spot-checked study
characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (TNH and JS) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by involving
another review author (PA). We assessed the risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective reporting.
7. Other bias.
We assessed selective outcome reporting bias by comparing the
outcomes reported with the outcomes planned based on clinical
trial registries/published protocols.
We graded each potential source of bias as high, low or unclear and
provide a quote from the study report together with a justification
for our judgement in the 'Risk of bias' table. We summarised
the 'Risk of bias' judgements across di"erent studies for each of
the domains listed. Where information on risk of bias related to
unpublished data or correspondence with a trialist, we noted this
in the 'Risk of bias' table.
When considering treatment e"ects, we took into account the risk
of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the review
We conducted the review according to the published protocol and
reported any deviations from it in the Di"erences between protocol
and review section of the review (Ni hlci 2018).
Measures of treatment e8ect
It was our intention to conduct the meta-analysis using the
most informative outcome and matching methods. Given that our
Mechanical assist devices for acute cardiogenic shock (Review)
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primary outcome was patient survival this would (ideally) involve
the use of individual participant data (IPD) and the tools of survival
analysis. Therefore, we contacted the authors of studies identified
in the review to request this data. If such data were available for a
su"icient number of studies, we would have performed the meta-
analysis using Cox Regression with mixed e"ects, following the
recommendations of a review of methods (Austin 2017). We would
then have conducted analysis using Poisson Regression modes and
reported hazard ratios (HRs) (Simmonds 2005). However, we were
unable to obtain IPD in all cases, and it was necessary to resort to
using aggregated data. In the case that we were required to use
aggregate data, we opted for binary survival at 30 days.
In addition to the primary measures, we collected and reported on
outcomes such as overall survival, survival to transplant, survival
to unsupported cardiac function and major adverse events where
possible. We reported confidence intervals (CI) of time to death
and time to major adverse events, along with point estimates. We
planned to describe dichotomous data relating to status at a fixed
time point using risk ratios (RRs) with corresponding CI (Higgins
2011). For continuous outcomes, we calculated the mean di"erence
(MD) between the treatment arms at the end of follow-up, if all trials
measured the outcome on the same scale, otherwise we pooled
standardised mean di"erences (SMDs), with 95% CI.
Unit of analysis issues
Where studies reported multiple observations for the same
participant, we included the data according to the closest time
point where applicable (e.g. survival at 30 days and survival at one
year). For quality of life data, we planned to include the last follow-
up point collected and, for adverse event data, we included the
first event in meta-analyses and described additional events for the
same individual in the text.
In multiple-arm studies, where more than two interventional arms
met the eligibility criteria, we planned to combine the two device
arms to have a single comparator (best current intensive care
management, including IABP and inotropic support).
As the intervention was in the setting of a life-threatening event,
cross-over trials would not be possible, thus we did not anticipate
finding cross-over trials.
To avoid unit of analysis errors in cluster-RCTs, we conducted
the analysis at the same level as the allocation, using a
summary measurement from each cluster. Then the sample size
is the number of clusters and analysis proceeds as if the trial
was individually randomised (though the clusters become the
individuals). However, this might considerably, and unnecessarily,
reduce the power of the study, depending on the number and size
of the clusters; we planned to acknowledge this as a limitation.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data where
possible (e.g. when a study was identified as abstract only). Where
this was not possible, and the missing data were thought to
introduce serious bias, we explored the impact of including such
studies in the overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
We assessed heterogeneity qualitatively by comparing the clinical
and methodological characteristics of the included trials and by
visual inspection of forest plots to assess the degree of overlap in
the CIs.
We compared heterogeneity quantitatively using the Chi2 test of
heterogeneity and the I2 statistic in each analysis. We considered a
Chi2 test resulting in P less than 0.1 indicating significant statistical
heterogeneity. We interpreted I2 statistics in the following manner:
0% to 40%, potentially not important; 30% to 60%, moderate
heterogeneity; 50% to 90%, substantial heterogeneity and 75% to
100%, considerable heterogeneity (Deeks 2011).
If we found very high heterogeneity, we first checked the data
specifically, questioning any outliers. If the data were correct, we
would have explored the results to understand why there was
heterogeneity, and identify the factors that may be causing the
variation between studies. If we found any modifiers, we would
have cautiously reported the overall and subgroup analysis. We
noted that the subgroup analysis was rarely randomised and we
cautioned that our results should be considered observational and
hypothesis-generating, rather than definitive.
If we had identified substantial or considerable heterogeneity,
we would had report it and explored possible causes using
prespecified subgroup analysis.
If the studies were too dissimilar in clinical (population, setting,
intervention) and methodological heterogeneity (study design, risk
of bias) and there was a high level of heterogeneity on visual
inspection of the forest plots (I2 greater than 90% and Chi2 with P
less than 0.1), then we planned not to proceed with meta-analysis
(Higgins 2011).
Assessment of reporting biases
If we were able to pool more than 10 trials, we planned to create
and analyse a funnel plot to explore possible reporting biases for
the primary outcomes.
Data synthesis
We undertook meta-analyses only where this was meaningful,
that is, if the treatments, participants and the underlying clinical
question were similar enough for pooling to make sense.
We would have used a random-e"ects model for pooling of
treatment e"ects, since the studies would di"er in the mixes of
participants and in the implementations of MADs (Higgins 2011).
We would have presented all results with the corresponding 95%
CIs. We would have conducted all analyses according to the
guidelines in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), and with the statistical components of
Review Manager 5 soMware (Review Manager 2014).
If su"icient, clinically similar studies had been available, we
would have pooled the results in meta-analyses. For time-to-
event data, we would have pooled HRs using the generic inverse
variance facility of Review Manager 5 (Review Manager 2014). For
dichotomous outcomes, we would have calculated the RR for each
study and then pooled them. For continuous outcomes, we would
have pooled the MDs between the treatment arms at the end of
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follow-up if all trials measure the outcome on the same scale,
otherwise we would have pooled the SMDs.
We would have descriptively summarised the studies for which
pooling of results was not possible.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Neonatal (less than 28 days of age)/paediatric (28 days to 16
years of age)/adult (greater than 16 years of age).
2. Cause of ACS/ischaemic heart disease/cardiomyopathy/acute
myopericarditis.
3. MAD compared with IABP.
4. MAD compared with best medical therapy excluding IABP.
5. Percutaneous MADs (pMAD) (using Seldinger insertion
technique) versus surgical MADs (inserted via sternotomy/
thoracotomy).
6. Long-term MCS devices (durable LVAD) compared with short-
term MCS devices (for example, ECMO, Impella).
7. Participants who had refractory cardiac arrest compared with
participants with no cardiac arrest at the time of device
implantation.
We used the following outcomes in subgroup analyses.
1. Survival (to discharge/30 days/1 year/to end of follow-up).
2. Major adverse events (to discharge/30 days/1 year/to end of
follow-up).
We used the formal test for subgroup interactions in Review
Manager 5 (Review Manager 2014).
Sensitivity analysis
We planned to carry out the following sensitivity analysis.
1. Only including studies with a low risk of bias across all domains.
Brief economic commentary
We developed a brief economic commentary based on current
methods guidelines to summarise the availability and principal
findings of trial-based and model-based economic evaluations
(cost-analyses, cost-e"ectiveness analyses, cost-utility analyses
and cost-benefit analyses) (Shemilt 2011; Shemilt 2017), that
compare the use of MADs to best current intensive care
management, including IABP and inotropic support. We identified
relevant studies for this brief economic commentary during
searches conducted for the review and during supplementary
searches performed in accordance with search strategies
developed by the Cochrane Economics Methods Group (Shemilt
2017). This commentary focused on the extent to which principal
findings of eligible economic evaluations indicated that an
intervention might be judged favourably (or unfavourably) from an
economic perspective, when implemented in di"erent settings.
Reaching conclusions
We based our conclusions only on findings from the quantitative or
narrative synthesis of included studies for this review. We avoided
making recommendations for practice and our implications for
research would suggest priorities for future research and outline
any remaining uncertainties in the area.
Summary of findings and assessment of the certainty of the
evidence
We created a 'Summary of findings' table with the following
outcomes and two time points.
Primary
1. Survival (30 days/end of follow-up).
2. Survival (to transplant or unsupported cardiac function/end of
follow-up).
Secondary
1. Quality of life (using a validated quality of life scale or
questionnaire; 30 days/end of follow-up).
2. Major adverse cardiovascular events (30 days/end of follow-up).
3. Dialysis-dependent (30 days/end of follow-up).
4. Length of hospital stay and length of intensive care unit stay.
5. Major adverse events, for example, deep sternal wound
infection, prolonged ventilation (30 days/end of follow-up).
The comparison described in the 'Summary of findings' table would
be MADs compared to best current intensive care management,
including IABP and inotropic support.
We used the five GRADE considerations (study limitations,
consistency of e"ect, imprecision, indirectness, and publication
bias) to assess the quality of a body of evidence as it relates to
the studies which contribute data to the meta-analyses for the
prespecified outcomes. We used methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), using
GRADEpro GDT soMware (GRADEpro GDT). Two review authors (CC
and JS) independently assessed the quality of the evidence and
decided on downgrading and upgrading. If no agreement could
be reached, a third review author (PA) resolved the disagreement.
We justified all decisions to downgrade or upgrade the quality
of the evidence using footnotes and we provided comments to
aid the reader's understanding of the review where necessary. We
planned to create one overall 'Summary of findings' table for our
main analysis of MADs compared to best current intensive care
management (inotropic support and IABP).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies tables.
Results of the search
The searches resulted in 5616 citations and an additional 11
references were identified from the papers' reference lists and
review of the ongoing clinical trials. We removed 1101 duplicates,
resulting in 4515 citations for screening. See Figure 1 for full details
of the process.
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Figure 1.   Study flow diagram. RCT: randomised controlled trial.
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Figure 1.   (Continued)
 
We excluded 4473 records on the basis of information in the title
and abstract. We retrieved the full text of 42 references, which
were screened independently by two review authors (TNH and CC).
Thirty of these did not meet the inclusion criteria.
Twelve references of five RCTs met the inclusion criteria, and were
included in the review. One trial had four publications (Thiele 2005),
two trials had three publications (Ouweneel 2017; Seyfarth 2008),
one trial had one paper (Burkho" 2006), and one trial was described
in a conference abstract only (Bonnefoy-Cudraz 2014).
The search for conference proceedings, meeting abstracts
and ongoing trials in databases such as ClinicialTrials.gov
(clinicaltrials.gov) yielded four ongoing trials relevant to this review
(DanGer Shock Trial; ECLS-SHOCK; ECMO-CS; EuroShock).
Included studies
Five prospective RCTs randomised people with ACS to a MAD or
best medical management including the use of an IABP. Two studies
included all causes of ACS (Burkho" 2006; Thiele 2005), and three
studies included people with ACS only caused by acute myocardial
infarction (Bonnefoy-Cudraz 2014; Ouweneel 2017; Seyfarth 2008).
The two studies that included all causes of ACS randomised
participants to the TandemHeart percutaneous VAD while those
that included people with ACS due to acute myocardial infarction
were randomised to the percutaneous Impella CP (Burkho" 2006;
Thiele 2005).
The total number of participants included in the five studies was
162 (13 to 41 participants included in each study). Four studies
described the gender of the 148 participants, 75% of who were male
(Burkho" 2006; Ouweneel 2017; Seyfarth 2008; Thiele 2005). The
number of centres ranged from one (Thiele 2005) to 12 (Burkho"
2006). The mean age of participants receiving MAD ranged from 58
to 65.7 years and those in the control group from 58 to 67 years.
Three studies described the mean lactate concentration prior to
initiating treatment (Burkho" 2006; Ouweneel 2017; Thiele 2005);
in the MAD group this ranged from 4.1 mg/dL (Burkho" 2006) to
7.5 mg/dL (Ouweneel 2017), and in the IABP group from 3.8 mg/dL
(Thiele 2005) to 8.9 mg/dL (Ouweneel 2017).
Of note, there were no studies investigating people aMer
cardiotomy shock, and there were no studies that included people
under the age of 18 years. In the people who presented with acute
myocardial infarction, coronary revascularisation was performed
prior to initiation of mechanical support in 69% of cases (Ouweneel
2017; Thiele 2005). Two studies described the time from diagnosis
to initiation of support, which ranged from 4.5 hours to 11 hours
and was similar in the MAD and IABP groups (Seyfarth 2008; Thiele
2005). Three studies described the duration of treatment (Burkho"
2006; Seyfarth 2008; Thiele 2005); the mean ranged from 23 hours to
four days, with those in Seyfarth 2008 having the shortest duration
of support and Thiele 2005 the longest.
Excluded studies
We excluded 22 studies. Of these, 11  investigated an
ineligible cohort whereby MADs were used in people with chronic
heart failure, or in cohorts of high-risk percutaneous interventions
(Characteristics of excluded studies table).
Ongoing studies
We found four ongoing studies (DanGer Shock Trial; ECLS-SHOCK;
ECMO-CS; EuroShock; Characteristics of ongoing studies table).
Risk of bias in included studies
The risk of bias of each study is summarised in Figure 2 with details
for each judgement provided in the Characteristics of included
studies table.
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Bonnefoy-Cudraz 2014 ? ? ? ? - + ?
Burkhoff 2006 ? ? ? ? + + ?
Ouweneel 2017 + + ? + + + +
Seyfarth 2008 ? ? ? ? + + ?
Thiele 2005 + + ? ? + + +
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Allocation
Random sequence generation
Random sequence generation was unclear in three studies as
there was no clear method described to how the randomisation
processes was performed (Bonnefoy-Cudraz 2014; Burkho" 2006;
Seyfarth 2008). Two studies were clear regarding the timing of
randomisation and method of doing so and were therefore at low
risk of bias in this domain (Ouweneel 2017; Thiele 2005).
Allocation concealment
Allocation concealment was unclear in three studies (Bonnefoy-
Cudraz 2014; Burkho" 2006; Seyfarth 2008). Seyfarth 2008 was
a prospective two centre RCT that, aMer initial assessment of
haemodynamics, randomly assigned eligible participants to either
treatment with IABP or Impella LP2.5, but further details of the
randomisation were not clarified. In Burkho" 2006, there was a roll-
in phase of nine participants into the study prior to initiation of the
randomisation of the subsequent 33 participants, the method of
randomisation was not described. Bonnefoy-Cudraz 2014 did not
describe any methods.
Allocation concealment was at low risk of bias in the remaining
two studies (Ouweneel 2017; Thiele 2005). Thiele 2005 performed
randomisation by drawing sealed envelopes and Ouweneel 2017
performed it in a 1:1 ratio using an Internet-based application.
Blinding
Performance bias unclear in all the studies. None of the studies
described any methods of blinding of participants or personnel.
Detection bias was low in one study where the outcome assessment
was clearly blinded as an independent clinical event committee
adjudicated the events (Ouweneel 2017). Imaging parameters were
assessed by independent local core laboratories that were blinded
to the other trial data and randomisation outcome (Ouweneel
2017). The other four studies did not describe any attempts at
blinding the outcome assessors, thus were deemed to have unclear
risk for detection bias (Bonnefoy-Cudraz 2014; Burkho" 2006;
Seyfarth 2008; Thiele 2005).
Incomplete outcome data
Attrition bias was low in four studies as they described complete
outcome data for the 30-day survival outcome. One participant was
lost to follow-up when assessing the six-month outcome (Ouweneel
2017). One study was at high risk for attrition as two randomised
participants were not included or accounted for in the analysis
(Bonnefoy-Cudraz 2014).
Selective reporting
Selective reporting bias was low as all that was described in
the methods of all five studies were reported and the data were
complete in all studies.
Other potential sources of bias
There were no other identified biases in the included studies.
E8ects of interventions
See: Summary of findings 1 Mechanical assist devices compared
to intra-aortic balloon pump for acute cardiogenic shock at 30-day
follow-up
Meta-analysis was performed only to assess the 30-day survival as
there was insu"icient data to perform any further meta-analysis.
Survival (30 day)
The results from the five studies with 162 participants showed that
there was little or no e"ect  in 30-day survival, with an RR of 1.01
(95% CI 0.76 to 1.35). The GRADE of the evidence was classed as very
low which means we are uncertain about the finding.
One of the five trials was powered to assess an absolute reduction in
the 30-day survival (Ouweneel 2017), the others had 30-day survival
as secondary outcomes. Ouweneel 2017 reported that there was no
significant di"erence in 30-day survival in the pMAD group (54%)
versus the IABP group (50%), with an HR of 0.96 (95% CI 0.42 to
2.18).
Overall, of the 162 participants included, 84 had MAD, 40 of whom
survived to 30 days (47.6% survival) and 78 had IABP, of whom 39
survived (50% survival).
No study described whether participants went on to have a
transplant or unsupported cardiac care.
Subgroup analysis assessing the type of MAD comparing those who
received TandemHeart (two studies; Burkho" 2006; Thiele 2005) to
those who received other devices (Bonnefoy-Cudraz 2014: Impella
LP 5.0 plus IABP; Ouweneel 2017: Impella CP plus IABP: Seyfarth
2008: Impella CP) demonstrated no statistical di"erence between
the two groups' survival outcomes at 30 days (Chi2 = 0.20, df = 1 (P
= 0.66); I2 = 0%).
Survival (to transplant or unsupported cardiac function/end of
follow-up)
None of the studies gave details regarding survival beyond 30 days
and there were no data regarding the number of participants who
survived to transplant or unsupported cardiac function.
Quality of life
None of the studies assessed quality of life in people who
underwent treatment for ACS with IABP or MAD.
Major adverse cardiovascular events
Three studies described major adverse cardiovascular events
in a heterogeneous manner (Ouweneel 2017; Seyfarth 2008;
Thiele 2005). There were no clear definitions for major
adverse cardiovascular events in any of the published studies.
Cerebrovascular accident was described to have occurred in one
participant who had a MAD and one participant who had IABP
only; these were both in Ouweneel 2017 and both CVA were
ischaemic. Ouweneel 2017 was the only study to describe if any
cases had myocardial reinfarction reporting that this occurred
in one participant who had MAD and two participants who had
IABP only. Ouweneel 2017 described that one participant had a
major vascular complication, with a retroperitoneal bleed aMer
pMAD insertion. Limb ischaemia occurred in three of the MAD
group and none in the IABP group. Thiele 2005 described that
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seven participants developed limb ischaemia following insertion
of a 17-French arterial cannula. Limb ischaemia could be resolved
by surgical approach in three participants and by percutaneous
approach in four participants. Seyfarth 2008 described one case
of limb ischaemia requiring surgery aMer device explantation in a
participant assigned to Impella MAD.
Dialysis-dependent
Only one study described if any cases required renal replacement
therapy following the episode of ACS (Ouweneel 2017). They
described that 33% of the MAD group and 29% of the IABP group
required renal replacement therapy.
Length of hospital stay
One study described the length of hospital stay aMer initiation of
treatment (Ouweneel 2017). The mean length of stay in the MAD
group was 16 days (range 3 days to 26 days) and in the IABP alone
group 10 days (range 6 days to 24 days).
Length of intensive care unit stay
Ouweneel 2017 was the only study to report length of intensive care
unit stay. The mean length of stay in the MAD group was 7 days
(range 3 to 16 days), and in the IABP alone group was 7 days (range
4 to 10 days).
Major adverse events
Three studies described major adverse events (Burkho" 2006;
Ouweneel 2017; Thiele 2005). Burkho" 2006 described one incident
of TandemHeart failure and one event where the device had to
be removed because of a device-related problem (blood clotting
in the cannula; activated clotting time documented to be 182
seconds, which is less than the recommended 200 seconds to
250 seconds). They described that systemic infection or sepsis
occurred in four (21.1%) of the MAD group and five (35.7%)
of the IABP group. Ouweneel 2017 described major bleeding
occurred in eight (33%) of the MAD group and two (8%) of the
IABP group. They postulated the reason for this was those with
mechanical support received heparin in addition to standard
dual antiplatelet therapy aMer percutaneous coronary intervention
(PCI). Thiele 2005 described that 13 (61%) participants in the
VAD group and three (15%) participants in the IABP group had
signs of disseminated intravascular coagulation (DIC). In the three
participants with IABP, DIC was mild and could be resolved by
substitution with antithrombin III. In eight participants with VAD,
DIC was severe with subsequent haemorrhagic diathesis.
D I S C U S S I O N
Summary of main results
This systematic review identified five prospective RCTs studying
adults with ACS who were randomised to treatment with MADs
or current best medical practice including the use of an IABP.
Two studies included all causes of ACS and the MAD used was
TandemHeart and two studies included only cases of cardiogenic
shock secondary to acute myocardial infarction and the MAD used
was Impella.
None of the studies were powered to assess if MADs improve
survival in people with ACS, thus the primary objective of this
review was unachievable. Four studies described 30-day outcomes
and there was little or no e"ect in the 30-day survival. No RCT
assessed survival to transplant or unsupported cardiac function
beyond six months.
Major adverse cardiovascular rates and major adverse event rates
are not described consistently across the four trials and we are
unable to conclude whether MAD led to an increased rate of
complications. Three trials described limb ischaemia and found a
trend towards an increase rate of limb ischaemia with MAD. This
may be an issue with the catheter size as 33% of the participants
in Thiele 2005 who had MAD with TandemHeart and a 17-French
catheter had issues with peripheral limb ischaemia.
Based on the current published RCTs, we were unable to assess and
formulate a brief economic commentary, and subgroup analysis
was only possible for one outcome.
Overall completeness and applicability of evidence
There are several limitations to the evidence base reviewed. Both
the number of trials that met the inclusion criteria for the review
and also the number of participants included in the review were
low. Not all the prespecified outcomes for the review were included
in all the trials and some were not reported by any included trial.
The condition studied, with its acute nature, rapid deterioration
and high mortality make RCTs challenging to undertake.
There are several di"erent devices for MCS, two di"erent forms
were included in this review; two trials (74 participants) utilised
the TandemHeart and recruited between 2002 and 2004 and 2000
and 2003; two trials (74 participants) utilised the Impella device
and recruited between 2012 and 2015 and 2004 and 2007. Further
devices have been developed and are being developed and it is
likely that there may be di"erences in the e"ects between devices.
The small number of participants included did not permit subgroup
analysis to compare e"ect sizes according to device type. With the
available evidence, we were unable to determine if MCS did o"load
pharmacological support or not.
Research is oMen undertaken at larger academic medical
institutions which oMen carry out higher volumes of procedures, it
is established that health outcomes are improved in high-volume
centres and it may be that outcomes would not be so good and
adverse event rates higher in those undergoing MCS in smaller
cardiac surgical centres.
Quality of the evidence
A summary of the findings and strength of evidence for comparing
MCS and IABP can be found in Summary of findings 1.
The evidence for 30-day survival was downgraded to very-low
certainty, due to study limitations (risk of bias in key domains) and
very serious concerns about imprecision that related to the very
small sample size and wide CIs including both the possibility of
benefit and harm. Future evidence is highly likely to change the
estimated e"ect.
The quality of evidence for the secondary outcomes was
downgraded to very-low certainty. No studies described quality
of life outcomes. Three studies described major adverse
cardiovascular events 30-day follow-up (Ouweneel 2017; Seyfarth
2008; Thiele 2005), and three studies reported major adverse events
at 30-day follow-up (Burkho" 2006; Ouweneel 2017; Thiele 2005);
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reporting was heterogeneous without any clear definitions in any of
the studies. Dialysis-dependence, length of hospital stay and length
of intensive care unit stay were described in one trial each.
Potential biases in the review process
We all work to try to improve the outcomes in hopeless situations
and we have an inherent bias to try to save lives. All trials
under-represented women in their study populations (75% of the
participants in the studies were male). Due to the nature of the
intervention the trials were not blinded; however, due to the main
outcome being survival it is unlikely that a lack of blinding had an
impact on this. Despite extensive searches, it is possible that we
were not able to identify all relevant studies.
Agreements and disagreements with other studies or
reviews
The findings of this review are consistent with other reviews
published in this field. The European Society of Cardiology
updated their guidance on the management of cardiogenic shock
complicating myocardial infarction (ESC 2019), they concluded
that, despite an increasing number of pMAD data derived from
clinical trials on the e"ectiveness safety, di"erential indications
for di"erent devices and optimal timing are limited. The authors
of three of the RCTs described in this review, collaborated and
published a review and collaborative meta-analysis including
individual patient data concluded that there was no di"erence
in mortality for 148 included participants. They found that there
was improvement in arterial lactate and mean arterial blood
pressure aMer device insertion. Counterbalancing this, however,
were significantly more bleeding complications in the MAD group
(Thiele 2017).
The Uspella registry reported on 15,259 people with acute
myocardial infarction cardiogenic shock treated with Impella (2.5,
CP or 5.0) in 1010 US hospitals and, of the total patients, 51%
survived to explantation (Basir 2016 USpella registry). Of note,
there were wide variations in survival observed on hospital sites,
they found significant di"erences between survival at the time of
explantation across various settings (30% survival rate among the
lowest quintiles less than 1 Impella case/year versus 76% among
the top quintile greater than 7 cases/year; P < 0.001). They identified
two variables associated with improved survival, the timing of
the MAD and haemodynamic monitoring. Clinicians used MAD as
first-line treatment or as salvage aMer inotropic or balloon pump
therapy failure. Data on MAD was available in 5571 people and
they found that use of MCS devices as first-line treatment was
associated with a 59% survival rate as compared with 52% when
used as a salvage strategy (P < 0.001). When investigating the impact
of invasive haemodynamic monitoring using pulmonary artery
catheters on outcome in 13,984 people, they found that the survival
rate among people who received haemodynamic monitoring was
63% compared with 49% in those who did not (P < 0.001). They
found that older age was associated with a lower survival (OR 0.98,
95% CI 0.97 to 0.99; P < 0.0001). In people aged less than 50 years,
61.2% survived to explant versus 45.1% of people aged over 80
years of age) and that Impella used before PCI was independently
associated with better survival (OR 1.34, 95% CI 1.2 to 1.5; P <
0.001), and that Impella CP was also associated with better survival
compared with Impella2.5 (OR 1.28, 95% CI 1.12 to 1.47; P = 0.003).
International guidelines in ACS highlight the di"iculty both ethically
and practically in RCTs adequately powered to detect di"erences
in clinical outcomes achieved as a result most of the trials
have been underpowered and guideline recommendations are
driven mostly by expert consensus (ESC 2019). Currently, early
revascularisation is the only proven treatment to reduce mortality
in acute myocardial infarction complicated by cardiogenic shock
(Hochman 1999), but the extent of the revascularisation limited
to the culprit lesion only (Thiele 2017 CULPRIT Shock Trial). But,
despite the complexities and di"iculties in performing clinical
studies in cardiogenic shock, it now has been repeatedly shown
that such trials can be successfully performed and international
collaboration to build large cardiogenic shock research networks to
answer the multiple open questions in the treatment of cardiogenic
shock.
Currently there are four ongoing randomised control trials
investigating the role of MAD in cardiogenic shock, powered to
show a mortality benefit for MAD (one Impella, three VA ECMO).
DanGer Shock 2019 has published the trial design along with
the characteristics of the first 100 participants randomised. This
collaborative trial will be the first adequately powered trial to
address whether MCS with Impella CP can improve survival in
acute myocardial cardiogenic shock. This trial has clear protocols
published. Issues regarding consent are clear as in Denmark written
informed proxy consent from relatives is obtained and in Germany
the principle investigators' inability to obtain informed consent
due to the urgency of the situation should be backed up by an
independent physician, and the principle investigator assesses and
acts according to supposed patients will. All centres must have
direct access to an Internet-based randomisation system and if the
patient is randomised to the treatment then Impella CP is placed
before revascularisation. Patients with an out-of-hospital cardiac
arrest with persistent Glasgow Coma Scale less than 8 aMer return
of spontaneous circulation are excluded from this study and only
patients with arterial lactate greater than 2.5 mmol/L. In the ICU,
patients irrespective of randomisation group are recommended
to have invasive cardiovascular monitoring including a pulmonary
artery catheter. No weaning attempts are done in the initial 48
hours, if there is stability at 48 hours, weaning should be attempted.
If weaning leads to haemodynamic instability the device should be
maintained and daily weaning attempts performed. AMer one week
of support, escalation should be considered to venoarterial ECMO
or LVAD. Guidance on the management of complications from the
device is also clearly stipulated.
The published trials included in our review did not exclude people
with out-of-hospital arrest. In the case of the largest trial, IMPRESS
in Severe Shock trial, all their participants were mechanically
ventilator prior to randomisation, and, overall, 92% of the included
participants had an out-of-hospital cardiac arrest with a median
duration of chest compression of more than 20 minutes and
25% of resuscitated participants were resuscitated for more than
45 minutes implying a significant risk of hypoxic cerebral injury
(Ouweneel 2017). They found that the primary cause of death at
six months was brain damage in 46% and death due to refractory
cardiogenic shock occurred in 29% of the deceased participants. It
has been speculated that the inclusion of out-of-hospital cardiac
arrests contributed to the neutral result of the trial. Thus, the
DanGer Shock trial has excluded these patients (DanGer Shock
2019). However, they include people who had a cardiac arrest in
the catheterisation laboratory or aMer the arrival of emergency
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services. As we were unable to obtain individual patient data and
the numbers were so small, we were unable to perform a sensitivity
analysis for the cohort of patients without cardiac arrest in this
systematic review and meta-analysis.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We are uncertain about the e"ects of mechanical circulatory
support in improving survival for people with acute cardiogenic
shock.
Further use of the technology, risk stratification and optimising the
use protocols may help to improve the situation.
The results of this review should not have implication for practice.
Implications for research
The small number of participants included in this review and the
very-low quality of evidence indicate that further research is highly
likely to change the estimated e"ect.
An e"ort should be made for future trials to define and report
complications in a consistent manner as this would allow
comparisons across studies, and pooling of the data. This is crucial
in this field as sample sizes in these studies tend to be quite small.
The devices available for mechanical circulatory support and
clinicians experience in selecting patients and when to implant
them is fast developing. Most participants included in this review
were randomised pre-2010. Further research will be key in
identifying whether there are subgroups of patients who can
benefit from this treatment and the magnitude of this benefit.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: RCT
Study grouping: not described
Total duration of the study: not described
Number of study sites and locations: not described
Study setting: not described
Date of the study: not described
Bonnefoy-Cudraz 2014 
Mechanical assist devices for acute cardiogenic shock (Review)









Cochrane Database of Systematic Reviews
Participants People with CS secondary to AMI
Baseline characteristics not described
Total number of participants randomised to intervention: 15
Number of participants lost to follow-up: 2
Number of participants analysed: 13
Interventions Impella LP5.0 + IABP vs IABP alone
Intervention characteristics
MCS
• Type of MCS: LVAD Impella LP5.0 + IABP
• Duration from diagnosis to intervention: N/A
• Duration of treatment: N/A
• Concomitant medications: N/A
IABP
• Duration from diagnosis to intervention: N/A
• Duration of treatment: N/A
• Concomitant medications: N/A
Outcomes Haemodynamic effect
• CPI after 12 hours of support was increased but not significantly in people with the Impella LP5.0 +
IABP compared with people with IABP (LP5.0 + IABP: CPI 0.08 (SD 0.08) watt/m2; IABP: CPI –0.02 (SD
0.25) watt/m2; P = 0.415).
Survival: 30 day
• 30-day mortality was 28.6% (2 deaths 1 week after inclusion) in Impella LP5.0 + IABP group compared
to 0 in IABP group.








Length of hospital stay
• Not reported
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• Not reported
Identification Sponsorship source: not stated
Country: France
Setting: not reported
Authors name: E Bonnefoy-Cudraz




Notes Published as a conference abstract.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of selection not described.
Allocation concealment
(selection bias)





Unclear risk Not described.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk 2 participants randomised not included or accounted for in analysis.
Selective reporting (re-
porting bias)
Low risk Outcomes were objective and described for all cases that were accounted for
in analysis.
Other bias Unclear risk No information regarding how they dealt with minimising bias. The full paper





Methods Study design: RCT
Study grouping: parallel group
Total duration of the study: 2 years
Burkho8 2006 
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Number of study sites and locations: 12 sites in USA and Switzerland
Study setting: tertiary referral sites
Date of the study: April 2002 to April 2004
Participants Baseline characteristics
MCS
• Age (mean): 65.7 (SD 13.8) years
• Male gender n (%): 14 (74%)
• Lactate (mean): 4.1 (SD 4) mmol/L
• Smokers n (%): N/A
• pH: N/A
• Lung function: N/A
• Cause of CS: 57% AMI, most of the remaining had decompensated chronic heart failure.
IABP
• Age (mean): 60.3 (SD 10.7) years
• Male gender n (%): 9 (64%)
• Lactate (mean): 5.5 (SD 4.7) mmol/L
• Smokers n (%): N/A
• pH: N/A
• Lung function: N/A
• Cause of CS: 71% AMI, most of the remaining had decompensated chronic heart failure.
Inclusion criteria: aged ≥ 18 years; presented within 24 hours of developing CS; ad indwelling right
catheter for measurement of PCWP and Cardiac Index; CS defined as Cardiac Index V2.2 L/m2/minute,
MAP 70 mmHg, PCWP 15 mmHg and evidence of end-organ hypoperfusion (e.g. decreased urine out-
put, altered mental status) or the need for administration of high-dose pressor or inotropic support (or
both) to maintain the participant out of CS. People already having an IABP were eligible if they still met
haemodynamic criteria for CS.
Exclusion criteria: isolated right-side heart failure, coagulopathy, sepsis, severe peripheral vascular
disease, stroke within 6 months, ≥ 2+ aortic regurgitation and ventricular septal rupture.
Total number of participants randomised to intervention: 33
Number of participants lost to follow-up: 0
Number of participants analysed: 33
Interventions MCS vs IABP
Intervention characteristics
MCS
• Type of MCS: TandemHeart percutaneous VAD. 21-French leM atrial drainage cannula, extracorporeal
centrifugal pump rotating at 7500 rpm, femoral arterial cannula 15-French to 17-French that extended
to the iliac artery and a microprocessor based pump controller.
• Duration from diagnosis to intervention: N/A
• Duration of treatment: 2.5 days
• Concomitant medications: pressors and inotropic support in all cases
IABP
• Duration from diagnosis to intervention: N/A
• Duration of treatment: 2.5 days
Burkho8 2006  (Continued)
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• Concomitant medications: pressors and inotropic support in all cases
Outcomes Haemodynamic effect
• Compared with IABP participants receiving support with MCS had significantly greater increases in
Cardiac Index and greater decreases in PCWP. Changes in the cardiac output were directly proportion-
al to changes in Cardiac Index and increased by 2.1 (SD 1.3) L/minute (P < 0.05). MAP did not change
in IABP group, whereas it increased significantly in MCS group.
Overall outcomes
• Proportion of participants dying while on support (or within 24 hours of device removal), being
bridged to another treatment or capable of being weaned was similar in both groups. Overall, 30-day
survival was similar in both groups (MCS: 53%; IABP: 64%).
Survival
• 30-day survival: MCS: 10/19 (53%); IABP: 9/14 (64%)
• 1-year survival: not described




Major adverse cardiovascular events
• MCS: system failure 1, right side of the heart failure 1, cardiac tamponade 2, damage to blood vessels
2, distal leg ischaemia 4
• IABP: non-CVS embolic event 1, cardiac tamponade 1, distal leg ischaemia 2
Dialysis-dependent
• Not reported. The outcome stated was renal dysfunction (MCS: 4; IABP 3)
Length of hospital stay
• Not reported
Length of ICU stay
• Not reported
Major adverse events
• MCS: sepsis 4
• IABP: sepsis 5
Additional outcome notes
From the 33 randomised participants, 5 IABP and 7 MCS participants were bridged to another therapy
after enrolment in study. In the MCS group, 3 participants underwent extracorporeal membrane oxy-
genation, 2 underwent PCI, 1 underwent mitral valve repair; 5 of this group survived. In the IABP group,
4 participants bridged to leM VAD and 1 underwent PCI. 3 of these participants survived ≥ 30 days.
Identification Sponsorship source: Cardiac Assist Inc, Pittsburgh
Country: USA and Switzerland
Setting: tertiary referral centre
Authors name: Daniel Burkhoff
Burkho8 2006  (Continued)
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Institution: Cardiovascular Research Foundation, Orangeburg, NY, USA
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not stated. There was a roll-in phase where VADs were
inserted without randomisation in centres new to the technique. People with
IABP already in situ were eligible.
Allocation concealment
(selection bias)





Unclear risk Participants would have been aware of treatment method. Results were sent
to an independent clinical research organisation.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Thorough detail of outcomes for all enrolled.
Selective reporting (re-
porting bias)
Low risk Complete outcome data available for all cases.
Other bias Unclear risk Centres that had not utilised VAD therapy previously were allowed to utilise






Methods Study design: RCT
Study grouping: parallel group
Total duration of study: 2 years 4 months
Number of study centres and locations: 2 centres, Academic Medical Center, Amsterdam, the Nether-
lands and Haukeland University Hospital, Bergen, Norway
Study setting: tertiary referral centre
Date of the study: 24 May 2012 to 15 September 2015
Participants Baseline characteristics
MCS
• Age (mean): 58 (SD 9) years
• Gender: 18 men; 6 women
Ouweneel 2017 
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• Lung function: N/A
• Smoking history: N/A
• Lactate prior to initiation (mean): 7.5 (SD 3.2) mmol/L
• Cause of cariogenic shock: STEMI
IABP
• Age (mean): 58 (SD 11) years
• Gender: 20 men; 4 women
• Lung function: N/A
• Smoking history: N/A
• Lactate prior to initiation (mean): 8.9 (SD 6.6) mmol/L
• Cause of cariogenic shock: STEMI
Inclusion criteria: AMI with ST segment elevation complicated by severe CS in the setting of immedi-
ate PCI (severe CS defined as systolic blood pressure < 90 mmHg for > 30 minutes or need for inotrope
or vasopressors to maintain systolic blood pressure > 90 mmHg). To select a patient population in even
worse condition, patients only qualified if they were mechanically ventilated before randomisation.
Exclusion criteria: severe aorto-iliac arterial disease with impeding placement of IABP or MCS; known
severe cardiac aortic valvular disease; serious concomitant disease with a life expectancy < 1 year; par-
ticipation in this study or any other trial within the previous 30 days; coronary artery bypass grafting
within preceding week.
Pretreatment: baseline characteristics of groups were well balanced.
Number of participants randomised to intervention: 48
Number of participants lost to follow-up: 0
Number of participants analysed: 48
Interventions MCS vs IABP
Intervention characteristics
MCS
• Type of MCS: percutaneous Impella CP (maximum output 3.7 L/minute)
• Duration from diagnosis to intervention: N/A
• Duration of treatment: N/A
• Concomitant medications: 100% received inotropes/catecholamines
• Concomitant procedures: all participants underwent primary percutaneous intervention
IABP
• Duration from diagnosis to intervention: N/A
• Duration of treatment: N/A
• Concomitant medications: 100% received inotropes/catecholamines
• Concomitant procedures: all participants underwent primary percutaneous intervention
Outcomes Survival
• 30-day survival: MCS 54%; IABP 50%
• 1-year survival: not available
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• Not described
Major adverse cardiovascular events: all clinical outcomes at 6 months
• Cerebrovascular accident: 1 MCS; 1 IABP
• Major vascular complication: 1 MCS; 0 IABP
• Myocardial reinfarction: 1 MCS; 2 IABP
Dialysis-dependent
• MCS: 8/24 (33%); IABP: 7/24 (29%)
• Duration (median: MCS: 17 (25th to 75th percentile 5–29) days; IABP: 7 (25th to 75th percentile 2–9)
days
Length of hospital stay
• Median: MCS: 16 (25th to 75th percentile 3–26) days; IABP: 10 (25th to 75th percentile 6–24) days
Length of ICU stay
• Median: MCS: 7 (25th to 75th percentile 3–16) days; IABP: 7 (25th to 75th percentile 4–10) days
Major adverse event
• Major bleeding: MCS: 8 (33%); IABP 2 (8%)
• Haemolysis requiring extraction of the device: MCS: 2 (8%); IABP: 0 (0%)
Cause of death
• Primary cause of death in both groups was brain damage (MCS: 41% of deceased; IABP: 50% of de-
ceased). Death due to refractory CS occurred in 29% of deceased participants (MCS: 4/12; IABP: 3/12)
Additional outcome notes
Of the 24 MCS participants, 1 subsequently received Impella 5.0; 1 was already received IAVP support
before randomisation (inserted before start of the primary PCI) and was subsequently randomised af-
ter PCI to MCS (protocol violation); 1 did not receive MCS as the participant showed signs of recovery af-
ter randomisation prior to device therapy.
Of the 24 IABP participants, 1 subsequently received MCS and was transferred to another hospital for
treatment with extracorporeal life support oxygenation; 2 participants received an alternative device,
the Impella 5.0 after the IABP and 1 of those received subsequent extracorporeal life support and an
LVAD at another hospital.




Authors name: Dr José PS Henriques
Institution: Department of Intensive Care Medicine, Academic Medical Center University of Amsterdam
Email: j.p.henriques@amc.uva.nl
Address: Academic Medical Center, University of Amsterdam, AMC Heart Center, Meiberg-dreef 9, 1105
AZ Amsterdam, the Netherlands
Year: 2017
Ouweneel 2017  (Continued)
Mechanical assist devices for acute cardiogenic shock (Review)









Cochrane Database of Systematic Reviews
Notes Randomisation and placement of MCS or IABP took place after revascularisation except for 8 partici-
pants in whom MCS or IABP was initiated prior to revascularisation (MCS: 5; IABP: 3).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Allocation selection using a randomised 1:1 internet application.
Allocation concealment
(selection bias)






Unclear risk No description of methods of blinding for participants and personnel.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk An independent clinical event committee adjudicated the events. Imaging
parameters were assessed by independent local core laboratories that were




Low risk All outcome data were complete.
Selective reporting (re-
porting bias)
Low risk All outcome data were reported.





Methods Study design: prospective RCT
Study grouping: parallel group
Date of the study: September 2004 to January 2007.
Number of study centres and location: 2 study centres in Germany
Total duration of the study: approximately 3 years
Study setting: tertiary referral centre
Participants Baseline characteristics
IABP
• Age (median): 67 (IQR 55–80) years
• Male gender, n (%): 11 (85%)
• Smoking, n (%): 7 (54%)
• pH: N/A
• Lactate: N/A
• Baseline lung function: N/A
Seyfarth 2008 
Mechanical assist devices for acute cardiogenic shock (Review)









Cochrane Database of Systematic Reviews
• Cause of CS: post-AMI
MAD
• Age (median): 65 (IQR 55–80) years
• Male gender, n (%): 8 (62%)
• Smoking, n (%): 8 (62%)
• pH: N/A
• Lactate: N/A
• Baseline lung function: N/A
• Cause of CS: post-AMI
Inclusion criteria: AMI < 48 hours, confirmed by ischaemic symptoms for ≥ 30 minutes with elevated
cardiac markers or ST-segment elevation or leM bundle branch block. AMI suspected when participants
were resuscitated and cardiac markers or electrocardiographic changes (or both) met criteria for AMI/
acute coronary syndrome; CS defined using both clinical and haemodynamic criteria as previously de-
scribed in the SHOCK trial. Clinical criteria were hypotension (systolic blood pressure < 90 mmHg) and
heart rate > 90 beats/minute or need for positive inotropic drugs to maintain systolic blood pressure >
90 mmHg and end-organ hypoperfusion (cool extremities or urine output < 30 mL/hour) or pulmonary
oedema. Haemodynamic criteria were either Cardiac Index ≤ 2.2 L/minute/m2 of body surface area and
PCWP > 15 mmHg or an angiographically measured leM ventricular ejection fraction < 30% and leM ven-
tricular end diastolic pressure > 20 mmHg. Onset of shock had to be within 24 hours.
Exclusion criteria: aged < 18 years; prolonged resuscitation (> 30 minutes); hypertrophic obstructive
cardiomyopathy; definite thrombus in leM ventricle; treatment with IABP; severe valvular disease or
mechanical heart valve; CS caused by mechanical complications of AMI such as ventricular septal de-
fect, acute mitral regurgitation greater than second degree or rupture of ventricle; predominant right
ventricular failure or need for a right VAD; sepsis; known cerebral disease; bleeding with a need for sur-
gical intervention pulmonary embolism; allergy to heparin or any known coagulopathy; aortic regurgi-
tation greater than second degree; pregnancy and inclusion in another study or trial.
Pretreatment: no statistically significant differences between the study groups with respect to clinical
characteristics and baseline haemodynamics.
Number of participants randomised: 26
Number of participants lost to follow-up: 0
Number of participants analysed: 26
Interventions Intervention characteristics
MAD
• Type of MCS: Impella LP2.5
• Duration from diagnosis to intervention (median): 4.5 (IQR 3.8–13.2) hours
• Duration of treatment (median): 25 (IQR 6.0–41.0) hours
• Concomitant medications: 84% inotropic support
IABP
• Duration from diagnosis to intervention (median): 5.0 (IQR 3.3–13.0) hours
• Duration of treatment (median): 23 (IQR 14.1–34.1) hours
• Concomitant medications: 92% inotropic support
Outcomes Haemodynamic effect
• Change in Cardiac Index, which was greater in the MAD group (MAD: 0.49 (SD 0.46) L/minute/m2); IABP:
0.11 (SD 0.31) L/minute/m2; P = 0.02). MAP increased in the MAD group by 9.0 (SD 14) mmHg vs –1.2
(SD 16.2) mmHg in the IABP group.
Seyfarth 2008  (Continued)
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Overall outcome
• Overall survival similar in both groups with 6 participants who died in each group (54% survived to
30 days in both groups).
Survival
• 30-day survival: MCS: 7/13 (54%); IABP: 7/13 (54%)
• 1-year survival: N/A




Major adverse cardiovascular events
• Limb ischaemia: MCS: 1; IABP: 0
• Other complications: not described
Dialysis-dependent
• Not reported
Length of hospital stay
• Not reported








Authors name: Melchior Seyfarth
Institution: Deutsches Herzzentrum München
Email: seyfarth@dhm.mhn.de
Address: Deutsches Herzzentrum München, Lazarettstrasse 36, 80636 Munich, Germany
Year: 2008
Notes Interventions
The assigned device was implanted after revascularisation therapy and following the measurement of
baseline haemodynamic parameters.
Risk of bias
Bias Authors' judgement Support for judgement
Seyfarth 2008  (Continued)
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Random sequence genera-
tion (selection bias)
Unclear risk Stated the participants were randomly allocated to either device, but the
method of allocation not described.
Allocation concealment
(selection bias)





Unclear risk Unable to blind participants and personnel.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk No loss of follow-up.
Selective reporting (re-
porting bias)
Low risk Complete description of outcome data.





Methods Study design: RCT
Study grouping: parallel group
Date of study: August 2000 to December 2003
Number of study centres: 1
Study setting: Department of Internal Medicine/Cardiology, University of Leipzig-Heart Centre,
Strumpellstr. 39, 04289 Leipzig, Germany
Total duration of the study: 3 years and 5 months
Participants Baseline characteristics
TandemHeart VAD
• Age (median): 63 (IQR 57–70) years
• Male gender, n (%): 16 (76)
• Diabetes, n (%): 11 (52)
• Smoking, n (%): 9 (43)
• pH (median): 7.28 (IQR 7.24–7.36)
• Lactate prior to intervention (median): 4.5 (3.1–6.5)
• Lung function: not documented
• Cause of CS: AMI
IABP
• Age (median): 65 (IQR 59–73) years
Thiele 2005 
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• Male gender, n (%): 15 (75)
• Diabetes, n (%): 11 (55)
• Smoking, n (%): 6 (30)
• pH (median): 7.34 (IQR 7.28–7.38)
• Lactate prior to intervention (median): 3.8 (3.5–6.7)
• Lung function: not documented
• Cause of CS: AMI
Baseline clinical characteristics were similar for both groups.
Baseline haemodynamic characteristics were similar for both groups except for a higher PCWP in the
IABP group (MCS (median): 20.0 (IQR 18–23); IABP 27 (IQR 20–30); P = 0.02).
Inclusion criteria: he presence of CS complicating AMI and intention to revascularise the infarcted
artery by PCI as first-line treatment option. CS identified as: persistent systolic blood pressure < 90
mmHg or vasopressors required to maintain blood pressure > 90 mmHg; evidence of end organ failure
(e.g. urine output < 30 mL/hour, cold skin and extremities, and serum lactate > 2 mmol/L); evidence of
elevated leM ventricular filling pressures (pulmonary congestion or PCWP > 15 mmHg); and Cardiac In-
dex > 2.1 L/min/m2.
Exclusion criteria: aged > 75 years; mechanical complications of AMI; duration of CS > 12 hours; right
heart failure; sepsis; significant aortic regurgitation; severe cerebral damage; resuscitation > 30 min-
utes; severe peripheral vascular disease and other diseases with reduced life expectancy.
Number of participants analysed: 41
Number of participants lost to follow-up: 0
1 participant did not receive the MAD as the patient showed rapid haemodynamic improvement after
PCI but was included in the final analysis according to intention-to-treat principles.
Number of participants randomised to intervention: 41
Interventions Intervention characteristics
MCS
• Type of MCS: TandemHeart VAD; after transeptal puncture a venous inflow cannula was inserted into
leM atrium. Oxygenated blood was drawn and returned via a centrifugal pump and an arterial cannula
in the femoral artery to the lower abdominal aorta. To avoid limb ischaemia in smaller participants,
2 arterial cannulae of 12-French in both femoral arteries were recommended. System was capable of
delivering flow up to 4.0L/minute at 7500 rpm but the 12-French cannula limited flow to 3.0 L/minute.
• Duration (diagnosis to intervention) (median): 11.0 (IQR 6.8–18.80) minutes
• Duration of treatment (median): 3.5 (IQR 2.0–4.5) days
• Inotropes or vasopressors (median): 3.0 (IQR 1.0–3.0) days
IABP
• Type of IABP: Datascope Corporation IABP inserted percutaneously, heparin administered intra-
venously and all participants were initially on a pumping ratio of 1:1 with 100% balloon inflation.
• Duration (diagnosis to intervention) (median): 10.0 (IQR 5.3–25.5) minutes
• Duration of treatment (median): 4.0 (IQR 3.5–4.0) days
• Inotropes or vasopressors (median): 2.0 (IQR 1.0–4.0) days
Outcomes Haemodynamic outcomes
• CPI improved by MCS from 0.22 (IQR 0.19–0.30) W/m2 to 0.37 (IQR 0.30–0.47) W/m2 (P < 0.001) when
compared with IABP (from 0.22 (IQR 0.18–0.30) W/m2 to 0.28 (IQR 0.24–0.36) W/m2; P = 0.02; P = 0.004
for intergroup comparison). Time of first CPI measurement after device implantation was similar (MCS:
40.0 (IQR 25.5–53.5) minutes; IABP: 33.5 (IQR 19.0–50.5) minutes; P = 0.28).
Thiele 2005  (Continued)
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Overall outcomes
Survival
• 30-day survival: MCS: 57% survival; IABP: 55% survival




Major adverse cardiovascular events
• In the MCS group, 7 participants developed limb ischaemia after implantation of a 17-French arterial
cannula and 0 in the IABP group (P = 0.009).
Dialysis-dependent
• Not reported
Length of hospital stay
• Not reported
Length of ICU stay
• Not reported
Major adverse events
• 13 participants in the MCS group and 3 in the IABP group had signs of DIC. In 8 MCS participants, DIC
was severe with subsequent haemorrhagic diathesis. In 3 IABP participants, DIC was mild and could
be resolved by substitution with antithrombin III.
Identification Sponsorship source: Cardiac Assist, Pittsburgh
Country: Germany
Setting: Department of Internal Medicine/Cardiology, University of Leipzig-Heart Centre, Germany
Comments:
Authors names: Holger Thiele*, Peter Sick, Enno Boudriot, Klaus-Werner Diederich, Rainer Hambrecht,
Josef Niebauer, and Gerhard Schule
Institution: Department of Internal Medicine/Cardiology, University of Leipzig-Heart Centre
Email: thielh@medizin.uni-leipzig.de
Address: Department of Internal Medicine/Cardiology, University of Leipzig-Heart Centre, Strümpell-
straße 39, 04289 Leipzig, Germany
Notes Outcomes
Cause of death: 4 participants in each group 3 in IABP due to LHF in the first 2 hours then 1 within 24
hours of PCI due to MODS. In the MCS group, 0 died within the 24 hours. However, 4 participants died
between days 2 and 4 as a cause of MODS despite active circulatory support. 5 additional participants
died in each group after weaning during 30-day follow-up, resulting in an overall mortality of 45% in
the IABP group and 43% in the MCS group (log-rank, P = 0.86). In the MCS group, 3 participants died af-
ter weaning due to recurrent LHF, and 2 due to sepsis or MODS. The cause of death after IABP explanta-
tion was MODS in 3 and acute LHF in 2 participants. There were no 30-day mortality differences for par-
Thiele 2005  (Continued)
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ticipants with pre-PCI assist support (MCS: 44%; IABP: 56%) and for those with post-PCI support (MCS:
42%; IABP: 36%).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised by drawing sealed envelopes.
Allocation concealment
(selection bias)
Low risk Study specified that some appropriate safeguards were taken, i.e. sealed en-






Unclear risk Study did not describe whether the participants and personnel were blinded
or not.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk No missing data outcomes
Selective reporting (re-
porting bias)
Low risk All of the study's prespecified (primary and secondary) outcomes that were of
interest in the review were reported in the prespecified way.
Other bias Low risk Inherent risk of bias was minimised as much as possible.
Thiele 2005  (Continued)
See Appendix 2 for a glossary of terms.
AMI: acute myocardial infarction; CS: cardiogenic shock; CPI: Cardiac Power Index; CVS: cardiovascular system; DIC: disseminated
intravascular coagulation; IABP: intra-aortic balloon pump; IAVP: implantable aortic valvo-pump; ICU: intensive care unit; IQR: interquartile
range; LHF: leM heart failure; MAD: mechanical assist device; MAP: mean arterial blood pressure; MCS: mechanical circulatory support;
MODS: multiorgan dysfunction syndrome; N/A: not applicable; PCI: percutaneous coronary intervention; PCWP: pulmonary capillary
wedge pressure; pMCS: percutaneous mechanical circulatory support; pVAD: percutaneous ventricular assist device; RCT: randomised
controlled trial; rpm: revolutions per minute; SD: standard deviation; STEMI: ST elevation myocardial infarction; VAD: ventricular assist
device.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abraham 2012 Ineligible cohort – end-stage chronic heart failure not acute cardiogenic shock.
Abraham 2014 Ineligible cohort – end-stage chronic heart failure.
Agarwal 2015 Registry data – not an RCT.
Agrawal 2016 Review article – with no new RCT data for the relevant cohort.
Almond 2017 Ineligible cohort.
Alushi 2019 Cohort study – no RCT data.
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Study Reason for exclusion
Anderson 2006 Meeting abstract – registry data.
Basir 2019 Cohort study – no RCT data.
Birks 2009 Ineligible cohort.
Birks 2018 Prospective cohort study – end-stage heart failure.
Bluhm 2010 Prospective non-randomised trial.
Bol 2019 Ineligible cohort.
Bronicki 2013 Ineligible cohort chronic heart failure.
Brunner 2019 Letter with no reference to any additional RCT data.
Kar 2012 Review article – no additional RCT data.
Liu 2012 Non-randomised trial.
Morici 2018 Cohort study – no RCT data.
NCT03101787 Registered clinical trial – ineligible treatment in an ineligible cohort.
NCT03431467 Registered clinical trial – ineligible control group.
Patel 2011 Ineligible cohort – high-risk PCI not cardiogenic shock.
Saeed 2013 Ineligible cohort – chronic heart failure.
Vallabhajosyula 2017 Review article – with no new RCT data for the relevant cohort.
PCI: percutaneous coronary intervention; RCT: randomised controlled trial.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name DanGer shock
Methods Prospective randomised (1:1), multicentre, open-label trial in people with STEMI complicated by
cardiogenic shock
Participants 360 people with acute myocardial infarction cardiogenic shock undergoing primary percutaneous
coronary intervention for STEMI.
Interventions Percutaneous Impella CP 3.8L with the device implanted before revascularisation
Outcomes Primary outcomes
• Death (follow-up 6 months)
• Death from all causes
Secondary outcomes
• MACE (timeframe 6 months)
DanGer Shock Trial 
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• Major cardiovascular events, death, cardiac transplant, escalation to permanent leM ventricular
assist device, rehospitalisation with heart failure.
• Combined safety (timeframe 6 months)
• Combined safety comprising major bleeding, vascular complications and significant haemolysis.
• Renal function (timeframe 6 months)
• Glomerular filtration rate, use dialysis
• SIRS (timeframe 1 month)
• Development of SIRS
• Health economics (timeframe 6 months)
• Cost of treatments
• Haemodynamics (timeframe 7 days)
• Cardiac Power Index, lactate clearance, pulmonary capillary wedge pressure
Starting date December 2012
Contact information Jacob E Moller, MD
jem@dadlnet.dk
Notes The DanGer trial aims to be the first adequately powered randomised trial to address whether me-
chanical circulatory leM ventricular support with Impella CP can improve survival in acute myocar-
dial infarction cardiogenic shock.
The baseline characteristics of the first 100 randomised participants were published in the Ameri-
can Heart Journal (DanGer Shock 2019), the participants were in profound cardiogenic shock, and
people with out-of-hospital cardiac arrests were excluded.
Originally registered as the Danish Cardiogenic shock trial and the ALLOASSIST trial; due to slow re-




Study name Clinical study of extra-corporal life support in cardiogenic shock complicating acute myocardial in-
farction
Methods Randomised controlled trial studying standard treatment + ECLS vs standard treatment alone in
people with cardiogenic shock due to myocardial infarction.
Participants People with cardiogenic shock complicating acute myocardial infarction STEMI/non-STEMI
Interventions ECLS from Sorin
Outcomes Primary outcome
• LVEF on day 30 (timeframe 30 days)
Secondary outcomes
• 30-day mortality (timeframe 30 days)
• Lactate levels (timeframe up to 48 hours)
• Length of mechanical ventilation (timeframe 30 days)
• Long-term mortality at 6 and 12 months (timeframe up to 12 months)
• LVEF after 6 and 12 months (timeframe up to 12 months)
• Length of ICU stay (timeframe 30 days)
• Quality of life on day 30, after 6 and 12 months (timeframe up to 12 months)
ECLS-SHOCK 
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• 6-minute walk distance on day 30, after 6 and 12 months (timeframe up to 12 months)
• New York Heart Association classification on day 30, after 6 and 12 months (timeframe up to 12
months)
Starting date September 2015





Study name Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS)
Methods Randomised controlled trial
Participants Adults with acute cardiogenic shock
Interventions Immediate venoarterial ECMO
Outcomes Primary outcome
• Composite of death from any cause, resuscitated circulatory arrest and implantation of another
mechanical circulatory support device (timeframe: 30 days)
Secondary outcomes
• All-cause mortality (timeframe: 30 days)
• All-cause mortality (timeframe: 6 months)
• All-cause mortality (timeframe: 12 months)
• Neurological outcome (according to Cerebral Performance Category scale) (timeframe: 30 days)
Starting date 26 November 2014





Study name Testing the value to novel strategy and its cost efficacy in order to improve the poor outcomes in
cardiogenic shock (EUROSHOCK)
Methods Multicentre randomised controlled trial
Participants Adults with acute cardiogenic shock following acute coronary syndrome
Interventions Venoarterial ECMO
Outcomes Primary outcomes
• All-cause mortality (timeframe: at 30 days)
• Death from any cause
EuroShock 
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Secondary outcomes
• All-cause mortality or admission for heart failure (timeframe: at 12 months)
• Death from any cause, or admission to hospital for heart failure with typical symptoms (e.g.
breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated jugu-
lar venous pressure, pulmonary crackles and peripheral oedema) caused by a structural or func-
tional (or both) cardiac abnormality, resulting in a reduced cardiac output or elevated intracar-
diac pressures (or both) at rest or during stress.
• All-cause mortality (timeframe: at 12 months)
• Death from any cause
• Admission for heart failure (timeframe: at 12 months)
• Admission to hospital with clinical syndrome of heart failure, defined as per the European Soci-
ety of Cardiology guidelines as typical symptoms (e.g. breathlessness, ankle swelling and fatigue)
that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles
and peripheral oedema) caused by a structural or functional (or both) cardiac abnormality, result-
ing in a reduced cardiac output or elevated intracardiac pressures (or both) at rest or during stress.
Starting date January 2019
Contact information Anthony H Gershlick; ahg8@le.ac.uk
Notes  
EuroShock  (Continued)
ECLS: extracorporeal life support; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; LVEF: leM ventricular ejection




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Mechanical circulatory support (MCS) versus intra-aortic balloon pump (IABP)





Statistical method Effect size
1.1 30-day survival 5 162 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.76, 1.35]
1.1.1 TandemHeart device 2 75 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.64, 1.42]
1.1.2 Other device 3 87 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.71, 1.66]
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Analysis 1.1.   Comparison 1: Mechanical circulatory support (MCS)







Heterogeneity: Tau² = 0.00; Chi² = 0.50, df = 1 (P = 0.48); I² = 0%







Heterogeneity: Tau² = 0.00; Chi² = 1.02, df = 2 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.71)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 1.71, df = 4 (P = 0.79); I² = 0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi² = 0.20, df = 1 (P = 0.66), I² = 0%
















































M-H, Random, 95% CI
0.82 [0.46 , 1.46]
1.09 [0.63 , 1.89]
0.95 [0.64 , 1.42]
1.00 [0.49 , 2.04]
1.08 [0.63 , 1.87]
4.38 [0.25 , 76.54]
1.09 [0.71 , 1.66]
1.01 [0.76 , 1.35]
Risk Ratio
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Footnotes
(1) Impella LP2.5 device
(2) Impella CP
(3) Impella LP 5.0 plus IABP
 
 
A P P E N D I C E S
Appendix 1. Glossary
Acute cardiac failure: sudden loss of heart function.
Acute myopericarditis: sudden inflammation of the heart muscle or the lining of the heart.
Cardiogenic shock: develops when the heart muscle has been damaged so extensively it can no longer pump enough blood to maintain
the bodies function and if not reversed will lead to organ damage and death.
Continuous flow: the pressure in the person's arterial system is continuous and does not change and the person does not have a palpable
pulse.
Haemodynamic support: medical help to maintain the blood supply to vital organs.
Heart failure: the heart is unable to e"ectively pump blood around the body.
Intracorporeal ventricular assist device: is a pumping device which is situated inside the body that assists the heart to pump blood.
LeM/right ventricular end diastolic pressure: the pressure in the leM/right ventricle when the heart is at rest prior to contracting.
Myocardial infarction: heart attack.
Organ hypoperfusion: is a state where the organs are not receiving enough blood to receive adequate oxygen and nutrients to function/
stay alive.
Paracorporeal ventricular assist device: is a pumping device which is situated outside the body which is connected to the major blood
vessels to assist the heart to pump blood.
Percutaneous device: is a device that is inserted via a needle through the skin into a blood vessel.
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Peripartum cardiomyopathy: when a woman's heart muscle does not function well around the time of childbirth.
Persistent hypotension: continuous low blood pressure.
Postcardiotomy cardiogenic shock: where a person's heart is able to pump aMer open heart surgery.
Pulsatile flow: blood flow which has a variable pressure and the person has a pulse.
Refractory cardiogenic shock: the heart is no longer pumping adequately despite the maximum medical treatment.
ST elevation myocardial infarction: serious heart attack leading to heart muscle death.
Surgical device: is a device that is inserted via opening the body using a scalpel.
Takotsubo cardiomyopathy: broken heart syndrome, where the heart becomes suddenly weakened.
Univentricular/biventricular dysfunction: the heart has two pumping chambers, right and leM ventricle. If one is not working properly this
is univentricular dysfunction; if both are not working properly it is biventricular dysfunction.
Vasopressor/inotropic support: medications that increase blood pressure by helping the heart to pump stronger and faster.
Appendix 2. Search strategies
CENTRAL
#1MeSH descriptor: [Heart Failure] explode all trees
#2((heart or cardiac or myocardial) near/2 fail*)
#3MeSH descriptor: [Shock, Cardiogenic] this term only
#4(Cardiogenic near/2 shock)
#5#1 or #2 or #3 or #4
#6MeSH descriptor: [Heart-Assist Devices] this term only
#7((mechanical or heart) near/2 (assist or device*))
#8((ventric* or biventric*) near/2 assist*)
#9((ventric* or biventric*) near/2 device*)
#10(VAD or VADs or LVAD or LVADs or RVAD or RVADs or BIVAD or BIVADs)




#15(extracorporeal near/3 life support)
#16ECLS
#17ELS
#18#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
#19#5 and #18
MEDLINE Ovid
1 exp Heart Failure/
2 ((heart or cardiac or myocardial) adj2 fail*).tw.
3 Shock, Cardiogenic/
4 (Cardiogenic adj2 shock).tw.
5 1 or 2 or 3 or 4
6 Heart-Assist Devices/
7 ((mechanical or heart) adj2 (assist or device*)).tw.
8 ((ventric* or biventric*) adj2 assist*).tw.
9 ((ventric* or biventric*) adj2 device*).tw.
10 (VAD or VADs or LVAD or LVADs or RVAD or RVADs or BIVAD or BIVADs).tw.
11 Extracorporeal Membrane Oxygenation/
12 ECMO.tw.
13 (extracorporeal adj3 membrane).tw.
14 (extracorporeal adj3 mechanical).tw.
15 (extracorporeal adj3 life support).tw.
16 ECLS.tw.
17 ELS.tw.
18 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19 5 and 18
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20 randomized controlled trial.pt.






27 20 or 21 or 22 or 23 or 24 or 25 or 26
28 exp animals/ not humans.sh.
29 27 not 28
30 19 and 29
Embase Ovid
1 exp heart failure/ (423396)
2 ((heart or cardiac or myocardial) adj2 fail*).tw.
3 cardiogenic shock/
4 (Cardiogenic adj2 shock).tw.
5 1 or 2 or 3 or 4
6 heart assist device/
7 ((mechanical or heart) adj2 (assist or device*)).tw.
8 ((ventric* or biventric*) adj2 assist*).tw.
9 ((ventric* or biventric*) adj2 device*).tw.
10 (VAD or VADs or LVAD or LVADs or RVAD or RVADs or BIVAD or BIVADs).tw.
11 extracorporeal oxygenation/
12 ECMO.tw.
13 (extracorporeal adj3 membrane).tw.
14 (extracorporeal adj3 mechanical).tw.
15 (extracorporeal adj3 life support).tw.
16 ECLS.tw.
17 ELS.tw.
18 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17







26 (doubl$ adj blind$).tw.





32 double blind procedure/
33 randomized controlled trial/
34 single blind procedure/
35 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36 (animal/ or nonhuman/) not human/
37 35 not 36
38 19 and 37
Web of Science
# 17 #16 AND #15
# 16 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
# 15 #14 AND #3
# 14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4
# 13 TS=ELS
# 12 TS=ECLS
# 11 TS=(extracorporeal near/3 life support)
# 10 TS=(extracorporeal near/3 mechanical)
# 9 TS=(extracorporeal near/3 membrane)
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# 8 TS=ECMO
# 7 TS=(VAD or VADs or LVAD or LVADs or RVAD or RVADs or BIVAD or BIVADs)
# 6 TS=((ventric* or biventric*) near/2 device*)
# 5 TS=((ventric* or biventric*) near/2 assist*)
# 4 TS=((mechanical or heart) near/2 (assist or device*))
# 3 #2 OR #1
# 2 TS=(Cardiogenic near/2 shock)
# 1 TS=((heart or cardiac or myocardial) near/2 fail*)
Clinical Trial registers and other resources
#1 Cardiogenic shock
H I S T O R Y
Protocol first published: Issue 4, 2018
Review first published: Issue 6, 2020
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We planned to study survival at 30 days, one year, end of follow-up, to transplantation or unsupported cardiac care. However, the only
survival data available was for 30 days.
We planned to report on outcomes such as overall survival, survival to transplant, survival to unsupported cardiac function and major
adverse events where possible. We reported confidence intervals (CI) of time to death and time to major adverse events, along with point
estimates. We planned to describe dichotomous data relating to status at a fixed time point using risk ratios (RRs) with corresponding CI
(Higgins 2011). For continuous outcomes, we calculated the mean di"erence (MD) between the treatment arms at the end of follow-up, if
all trials measured the outcome on the same scale, otherwise we planned to pool standardised mean di"erences (SMDs). However, these
data were not provided in the studies.
We planned to carry out the following subgroup analyses.
1. Neonatal (less than 28 days of age)/paediatric (28 days to 16 years of age)/adult (greater than 16 years of age).
2. Cause of acute cardiogenic shock/ischaemic heart disease/cardiomyopathy/acute myopericarditis.
3. Mechanical assist device (MAD) compared with intra-aortic balloon pump (IABP).
4. MAD compared with best medical therapy excluding IABP.
5. pMADs (using Seldinger insertion technique) versus surgical MADs (inserted via sternotomy/thoracotomy).
6. Long-term MCS devices (durable leM ventricular assist device) compared with short-term MCS devices (for example, extracorporeal
membrane oxygenation, Impella).
7. Participants who had refractory cardiac arrest compared with participants with no cardiac arrest at the time of device implantation.
However, there were insu"icient data to do these analyses.
We planned to do an economic commentary, but there were insu"icient published data to do so.
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